CAMBRIDGE, Mass. and NEW YORK CITY – Nov. 12, 2014 – GNS Healthcare (GNS), a leading provider of big data analytics in health care, announced today that CHDI Foundation, Inc. (CHDI), a privately-funded, nonprofit biomedical research organization exclusively dedicated to Huntington’s disease, has committed to continuing their collaboration to accelerate the discovery process for therapeutics that will slow the progression of Huntington’s disease. Continue reading →

The 10th Annual HD Therapeutics Conference will be held February 23-26, 2015, at the Parker Hotel in Palm Springs, California. You can register here. The conference program is currently being finalized and will cover all aspects of drug discovery related to Huntington’s disease. Continue reading →

WILMINGTON, Mass. – Nov. 5, 2014 — Charles River Laboratories International, Inc. announced today that CHDI Foundation, Inc. has extended its ongoing collaboration for an additional five years through to 2019. The collaboration, which began in 2005, is focused on discovering novel drugs for Huntington’s disease. Continue reading →

Hamburg, Germany – 11 September 2014: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that CHDI Foundation, Inc. (“CHDI”) has extended and restated its collaboration with Evotec through 2017. The collaboration—which aims to find new treatments for Huntington’s disease, an inherited neurodegenerative disorder—means that CHDI will fund up to 52 full-time scientists at Evotec over the next three years. Continue reading →

Toronto, Canada & New York City, USA; June 4, 2014 – The Structural Genomics Consortium (SGC) and CHDI Foundation have entered into a unique open-access research collaboration to discover and characterize new drug targets for Huntington’s disease (HD) using structural and chemical biology.  In this first partnership of its kind, SGC and CHDI have explicitly agreed not to file for patents on any of the collaborative research and to make all reagents and knowledge available without restriction to the wider research community, including pharmaceutical, biotech, and academic research groups. Continue reading →

New York, June 2 2014: CHDI has appointed Thomas F Vogt, PhD as its new Vice President of Discovery and Systems Biology. Vogt and his group will work closely with the translational biology, chemistry, and clinical groups at CHDI to identify and validate biological targets to enable and accelerate the development of effective therapies for Huntington’s disease (HD). Continue reading →

EMERYVILLE, Calif., May 19, 2014 — KineMed, Inc. ( www.kinemed.com ) and CHDI Foundation, Inc. ( www.chdifoundation.org ) announced today an extension of their collaboration that uses KineMed’s translational biomarker platform to characterize and track the pathogenesis of Huntington’s disease (HD) and evaluate potentially therapeutic interventions. Continue reading →

Many different mouse models of Huntington’s disease are now available and the choice of which model(s) to use is a critical consideration that depends greatly on your particular research focus. Equally, good husbandry to breed and rear mouse colonies under rigorous quality-controlled conditions can ensure genetic integrity and the highest quality resources for HD research, which is integral to generating robust and reproducible results that can be compared across laboratories.

CHDI, The Jackson Laboratory, and PsychoGenics, Inc. have compiled A Field Guide to Working with Mouse Models of Huntington’s Disease that brings together current understanding of many of the established and emerging HD mouse models and their known advantages, disadvantages, peculiarities and pitfalls, and proposes standardized best practices to optimize their use in preclinical research and development. In particular, the manual emphasizes the importance of understanding how different models reflect disease phenotypes and mechanisms; the ‘best model’ to use will depend on the question being addressed. The goal is to improve the translation of results to the clinic and accelerate the pace of HD therapeutic research. Continue reading →